Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma

BACKGROUND: Sorafenib has been approved in the indication of unresectable hepatocellular carcinoma, but there are many cases in which administration of the drug is discontinued due to severe side effects. In this study, we compared the characteristics of patients who continued and discontinued soraf...

Descripción completa

Detalles Bibliográficos
Autores principales: Nojiri, Shunsuke, Kusakabe, Atsunori, Fujiwara, Kei, Shinkai, Noboru, Matsuura, Kentaro, Iio, Etsuko, Miyaki, Tomokatsu, Nomura, Tomoyuki, Sobue, Satoshi, Sano, Hitoshi, Hasegawa, Izumi, Ohno, Tomoyoshi, Takahashi, Yoshitsugu, Orito, Etsuro, Joh, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534393/
https://www.ncbi.nlm.nih.gov/pubmed/23293537
http://dx.doi.org/10.2147/CMAR.S38684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534393/
https://www.ncbi.nlm.nih.gov/pubmed/23293537
http://dx.doi.org/10.2147/CMAR.S38684

Ejemplares similares